SEMA4D and acute myeloid leukemia: A schematic diagram of a proposed pathway to describe the role of SEMA4D/PlexinB1 in AML is shown in Fig. 6SEMA4D may serve as a novel target for diagnostically relevant biomarkers and combination therapy in AML patients.